

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – July 13, 2016 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. June 8, 2016 DUR Minutes – Vote
- B. June 8, 2016 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Action Item – Update on Medication Coverage Authorization Unit/Opioid Prescriptions in Pregnant Women – See Appendix B

- A. Medication Coverage Activity for June 2016
- B. Pharmacy Help Desk Activity for June 2016
- C. Opioid Prescriptions in Pregnant Women – Vote

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Zytiga® (Abiraterone), Jevtana® (Cabazitaxel), Xtandi® (Enzalutamide), Xofigo® (Radium-223 Dichloride), and Provenge® (Sipuleucel-T) – See Appendix C

- A. Introduction
- B. Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Dyanavel™ XR (Amphetamine Extended-Release), QuilliChew ER™ (Methylphenidate Extended-Release), and Adzenys XR-ODT™ (Amphetamine Extended-Release) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Rexulti® (Brexipiprazole), Vraylar™ (Cariprazine), and Aristada™ (Aripiprazole Lauroxil) – See Appendix E

- A. Indication(s)
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Albenza® (Albendazole) and Emverm™ (Mebendazole) – See Appendix F

- A. Introduction
- B. Regimen Comparison
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize OsmoPrep® (Sodium Phosphate Monobasic/Sodium Phosphate Dibasic), Prepopik® (Sodium Picosulfate/Magnesium Oxide/Citric Acid), Suclear® (Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate/PEG-3350/Sodium Chloride/Sodium Bicarbonate/Potassium Chloride), and SUPREP® (Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate) – See Appendix G

- A. Cost Savings
- B. Bowel Preparation Medications Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Nuessa™ (Metronidazole Vaginal Gel 1.3%), Zyclara® (Imiquimod Cream), and Kristalose® (Lactulose Packets) – See Appendix H

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize H.P. Acthar® Gel (Corticotropin Injection) – See Appendix I

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Econazole Nitrate 1% Cream and Clotrimazole 1% Solution – See Appendix J

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Ocaliva™ (Obeticholic Acid) – See Appendix K

- A. Primary Biliary Cholangitis (PBC) Background Information
- B. Ocaliva™ (Obeticholic Acid) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

14. Annual Review of Opioid Analgesics and Buprenorphine Products & 30-Day Notice to Prior Authorize Belbuca™ (Buprenorphine Buccal Film), Dolophine® (Methadone), MorphaBond™ (Morphine Extended-Release), Xtampza™ ER (Oxycodone Extended-Release), & Probuphine® (Buprenorphine Implant) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Opioid Analgesics and Buprenorphine Products
- C. Prior Authorization of Opioid Analgesics & Buprenorphine Products
- D. Opioid Analgesic Utilization Trends
- E. Market News and Updates
- F. Belbuca™ (Buprenorphine Buccal Film) Product Summary
- G. MorphaBond™ (Morphine Extended-Release) Product Summary
- H. Xtampza™ ER (Oxycodone Extended-Release) Product Summary
- I. Probuphine® (Buprenorphine Implant) Product Summary
- J. College of Pharmacy Recommendations
- K. Utilization Details of Opioid Analgesics
- L. Utilization Details of Buprenorphine Products

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

15. Annual Review of Anti-Ulcer Medications and 30-Day Notice to Prior Authorize Dexilant™ SoluTab (Dexlansoprazole Delayed-Release Orally Disintegrating Tablets) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Ulcer Medications
- C. Prior Authorization of Anti-Ulcer Medications

- D. Market News and Updates
- E. Dexilant™ SoluTab (Dexlansoprazole) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anti-Ulcer Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

16. Annual Review of Antidepressants – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Antidepressants
- C. Prior Authorization of Antidepressants
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Antidepressants

Non-presentation; Questions only:

17. Annual Review of Myalept® (Metreleptin) – See Appendix O

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Myalept® (Metreleptin)
- D. Prior Authorization of Myalept® (Metreleptin)
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

18. FDA and DEA Updates – See Appendix P

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

August 2016 not scheduled as a live meeting (packet only)

- A. Ocular Anti-Infectives
- B. Glaucoma Medications
- C. Prednisolone Special Formulations
- D. Alzheimer's Medications
- E. Nasal Allergy Medications
- F. Nonsteroidal Anti-Inflammatory Medications

*Future business subject to change.

20. Adjournment